Chinese scientists at Peking University (PKU) in Beijing have developed a new in vitro patient-derived tumor-like cluster (PTC) model, which predicted the outcomes of neoadjuvant and conventional chemotherapies in colon, gastric and breast cancer patients, with a clinical consistency of >93%.